1-3 of 3
Daniel E.H. Afar
Close
Sort by
Journal Articles

CS-1 Is Expressed in Nasal Type NK/T Cell Lymphomas and Angioimmunoblastic T-Cell Lymphomas: Implications for Targeted Therapy with Elotuzumab (HuLuc63).

Eric D Hsi, MD, Roxanne Steinle, Balaji Balasa, Audie Rice, PhD, Young-Hyeh Ko, MD, Daniel E.H. Afar, PhD
Journal: Blood
Blood (2008) 112 (11): 1779.
https://doi.org/10.1182/blood.V112.11.1779.1779
Published: 2008
Journal Articles

Low Levels of Circulating CS1, a Newly Identified Multiple Myeloma (MM) Antigen for a Novel Humanized HuLuc63 Monoclonal Antibody, Is Detected in MM Patient Sera and Correlates with Active Disease.

Yu-Tzu Tai, PhD, Audie G. Rice, Ph.D., Marav Leiba, M.D., Xian-Feng Li, M.S., Peter Burger, B.S., Weihua Song, M.D., Rao Prabhala, Ph.D., Myles Dillon, B.S., Edie Tolan, Ph.D., Xanling Xie, Ph.D., Teru Hideshima, M.D., Ph.D., Noopur Raje, M.D., Paul Richardson, M.D., Nihkil C. Munshi, M.D., Arnon Nagler, M.D., Herve Avet-Loiseau, M.D., Daniel E.H. Afar, Ph.D., Kenneth C. Anderson, M.D.
Journal: Blood
Blood (2007) 110 (11): 1509.
https://doi.org/10.1182/blood.V110.11.1509.1509
Published: 2007
Journal Articles

HuLuc63 in Combination Regimens with Conventional and Targeted Therapies Has Additive and Synergistic Anti-Tumor Activity in Pre-Clinical Models of Myeloma.

Audie G. Rice, Myles B.C. Dillon, Anne M. Van Abbema, Daniel E.H. Afar
Journal: Blood
Blood (2007) 110 (11): 2517.
https://doi.org/10.1182/blood.V110.11.2517.2517
Published: 2007